Lundbeck said it presented new data at the 2026 American Academy of Neurology annual meeting in Chicago from the INFUSE real-world study of Vyepti (eptinezumab). The company said patients reported improvements in migraine-related cognitive symptoms after treatment, including brain fog and difficulty making decisions.
Lundbeck said Sunday that it presented new data at the 2026 American Academy of Neurology annual meeting in Chicago, highlighting real-world changes in migraine-related cognitive symptoms after patients started Vyepti, or eptinezumab.
The company said the findings came from the INFUSE study and covered 6-month patient-reported outcomes. The population included patients who had experienced at least one prior anti-CGRP preventive treatment failure.
According to Lundbeck, symptoms associated with migraine-related cognitive impairment improved after treatment. The company cited brain fog, difficulty making decisions, reading-comprehension problems and trouble with complex tasks among the symptoms tracked.
The AAN program also lists Lundbeck's participation in an industry therapeutic update at the 2026 meeting. Lundbeck had previewed migraine-related data in advance of the conference, but the release on April 19 is the first public disclosure of these results.
The company did not say in the materials reviewed whether the data were presented as a poster, oral presentation or both.
Revision note
Initial automated publication.